Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YB1-X7 in Advanced Solid Tumors
NCT06889675Phase 1Recruiting
- Sponsor
- Shanghai Salvectors Biotechnology LTD.
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Live Biotherapeutic Products, Oncolytic Bacteria
- Countries
- 1
01
Overview
Phase 1, open-label trial of YB1-X7 in solid tumor (3 arms), sponsored by Shanghai Salvectors Biotechnology LTD. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
YB1-X7
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06889675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889675.